DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the THYROCARE TECH LTD (THYROCARE) share price today?

THYROCARE TECH LTD (THYROCARE) is trading at ₹520.6 on the NSE, down 1.26% on the day. Source: DocStoX.

What is the PE ratio of THYROCARE TECH LTD?

THYROCARE TECH LTD has a price-to-earnings (PE) ratio of 50.8 in the Healthcare sector.

What is the market capitalisation of THYROCARE TECH LTD?

THYROCARE TECH LTD has a market capitalisation of approximately ₹8,302 crore.

THYROCARE TECH LTD

THYROCARE·NSE·Healthcare

₹520.60▼ -6.65 (-1.26%)

Healthcare · Healthcare Service Provider

Debt-free and consistently profitable

Day₹514.10

₹531.15

52W₹343

₹161014%

Open

₹527.25

High

₹531.15

Low

₹514.10

Prev Close

₹527.25

Volume

2.22L

VWAP

₹520.71

Snapshot

Key fundamentals

Market Cap

₹8,302 Cr

P/E Ratio

50.84Expensive

P/B Ratio

16.59

EPS

₹10.24

Book Value

₹36.80

ROE

28.40%Strong

ROCE

35.00%Efficient

Dividend Yield

2.61%

Debt / Equity

0.09Low

Face Value

₹10.00

52W High

₹1610.00

52W Low

₹342.55

Sector

Healthcare

Industry

Healthcare Service Provider

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹66

▼ 87.3%downside

Trading at ₹521 — 87% above our estimate

BearFair valueBull

₹56₹66₹92

/100

Business quality — Solid

Growth 83Profitability 99Efficiency 50Valuation 48

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 3/9)

Strengths

Virtually debt-free balance sheet
Strong returns on equity (28%)
Capital is working hard (ROCE 35%)
Revenue compounding 16% over 3 years

Risks

Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

28% ROE fading to 12% over ~10 yrs, on ₹37 book

₹59

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹92

Analyst target

No analyst coverage

—

Blended fair value₹66

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Strong returns on equity (28%)
Capital is working hard (ROCE 35%)
Revenue compounding 16% over 3 years
Profit growing 37% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

50.8Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

28.4%Strong

Above 15% is considered healthy for Indian equities

ROCE

35.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.09Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹8,302 Cr

P/B

16.59

EPS

₹10.24

Div Yield

2.61%

What changed

Recent changes

Foreign investors+0.4% stake last quarter
Domestic institutions+0.5% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 50.8×

Growth

Strong

+16% rev CAGR

Profitability

Excellent

28.4% ROE

Financial health

Rock solid

D/E 0.09

Momentum

N/A

No technicals

Today

Trading activity

Delivery %53.4%

Turnover₹1156.69L Cr

Trades13,739

VWAP₹520.71

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+16.3%

+10.9%

10Y

+13.2%

Profit

+36.6%

+7.6%

10Y

+12.1%

EPS

+36.1%

+7.5%

10Y

+12.3%

Profile

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 131%

Watch-outs

Cons

Stock is trading at 14.0 times its book value
Promoters have pledged 100% of their holding.
Promoter holding has decreased over last 3 years: -10.2%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.42 pts; domestic institutions added 0.48 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

61%

Promoter

Promoters

60.9%-0.01

Public

10.2%-0.70

FII / FPI

5.4%+0.42

DII

21.0%+0.48

Others

2.5%

Total shareholders

73,377-4,592 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter60.92%

FII5.37%

DII20.99%

Public10.18%

Others2.54%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.